@article{oai:kindai.repo.nii.ac.jp:00020124,
 author = {Ohzeki, Takayuki and Hashimoto, Mamoru and Shimizu, Nobutaka and Minami, Takafumi and Nozawa, Masahiro and Nose, Kazuhiro and Yoshimura, Kazuhiro and Uemura, Hirotsugu},
 issue = {2},
 journal = {ACTA MEDICA KINDAI UNIVERSITY},
 month = {Dec},
 note = {[Abstract] Purpose: This study is to investigate the efficacy and safety of presurgical targeted molecular therapy with tyrosine kinase inhibitors (TKIs) and mammalian targets of rapamycin inhibitors (mTORIs) for advanced renal cell carcinoma in a Japanese population. Methods: We retrospectively identified patients with renal cell carcinoma treated with targeted molecules before tumor resection. Results: Between July 2008 and February 2014, 11 patients were treated with targeted molecular therapy and subsequently underwent resection. Operations were performed by open laparotomy in all cases for locally advanced and metastatic disease, with the exception of one patient who had an inoperable tumor. The average reduction rates of primary tumor and metastases were −14.9% (range, −47～ +18%) and −35.7% (range, −100～+40%), respectively. Cancer-related deaths tended to occur in patients who had weak reduction of primary tumor despite therapy. Two patients had minor perioperative complications, including wound healing delay and infection. Pathological analysis revealed clear cells in all cases. Conclusions: Surgical resection of renal cell carcinoma after targeted therapy was feasible with low morbidity in most patients. Presurgical therapy might help identify patients with renal cell carcinoma who have a poor prognosis and might not achieve survival benefit from cytoreductive surgery., application/pdf},
 pages = {69--74},
 title = {<Original> Presurgical targeted molecular therapy for advanced renal cell carcinoma: Long-term clinical outcomes in a Japanese population},
 volume = {43},
 year = {2018},
 yomi = {オオゼキ, タカユキ and ハシモト, マモル and シミズ, ノブタカ and ミナミ, タカフミ and ノザワ, マサヒロ and ノセ, カズヒロ and ヨシムラ, カズヒロ and ウエムラ, ヒロツグ}
}